Skip to main content
. 2018 Sep 4;2018(9):CD013102. doi: 10.1002/14651858.CD013102

Edwards 2014.

Methods Randomised trial
Participants 200 participants with cancer (intervention 100; control 100)
Cancer Centre
 Newfoundland, Canada
Year of study: Not stated.
Interventions The intervention patients received a visit from the seamless care pharmacist (SCP) prior to the initiation of chemotherapy. The visit included medication history reconciliation. The SCP checked medication against established regimen protocols, including a drug interaction check, recalculation of the dose, and verification of pertinent laboratory values. The patient’s hospital pharmacist, oncology nurse, and attending physician received copies of the report. The SCP counselled the patient on their treatment, identified and resolved any drug‐related problems. Patients were followed up by phone 2 days post‐chemotherapy to identify/resolve drug‐related problems.
Duration: unclear
Outcomes  
Notes Control group outcomes not presented
No useable quantitative data
Funding source: Funded through unrestricted research grants from Pfizer, Amgen, and Roche.
Conflict of interest: None stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) Low risk Patients were randomised 1:1 to the intervention group or the control group in the clinical trials department using a random‐number generator.
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel (performance bias) 
 All Outcomes/Outcome 1 Unclear risk Unclear
Blinding of outcome assessment (detection bias) 
 All Outcomes/Outcome 1 Unclear risk Unclear
Incomplete outcome data (attrition bias) 
 All outcomes Low risk Between group attrition < 10%.
Selective reporting (reporting bias) High risk No clear statement of outcomes
Other bias High risk Outcomes not presented. Length of study not stated